AP file photo

The $125 million sale of Sarepta's priority review voucher to Gilead made us wonder: Was it really as big of a bargain for Gilead as some believed? It's difficult to say, because it's only the fifth major transaction of a voucher. The latest value falls right in the middle, just like another Gilead bought. Here are the previous deals, as tracked by Duke University professor David Ridley:

  • $350 million. Buyer: AbbVie. Seller: United Therapeutics.
  • $245 million. Buyer: Sanofi. Seller: Retrophin.
  • $125 million. Buyer: Gilead. Seller: Knight Therapeutics.
  • $67.5 million. Buyers: Regeneron Pharmaceuticals and Sanofi. Seller: BioMarin.

The Food and Drug Administration grants priority review vouchers as an incentive for drug companies to get expedited approval for a medicine. There are still seven other vouchers out there. The most recent recipient? Marathon Pharmaceuticals. It received a fast pass as it got FDA approval for its Duchenne muscular dystrophy drug. The company has been lambasted nationally for setting an $89,000 list price and has delayed the U.S. launch of the drug.

Go deeper

Updated 1 hour ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios

  1. Politics: Trump calls Fauci a "disaster" on campaign call.
  2. Health: Coronavirus hospitalizations are on the rise — 8 states set single-day coronavirus case records last week.
  3. States: California to independently review FDA-approved coronavirus vaccines
  4. Wisconsin judge reimposes capacity limit on indoor venues.
  5. Media: Trump attacks CNN as "dumb b*stards" for continuing to cover pandemic.
  6. Business: Consumer confidence surveys show Americans are getting nervousHow China's economy bounced back from coronavirus.
  7. Sports: We've entered the era of limited fan attendance.
  8. Education: Why education technology can’t save remote learning.
Dion Rabouin, author of Markets
2 hours ago - Economy & Business

The 2020 holiday season may just kill Main Street

Illustration: Eniola Odetunde/Axios

Online retail and e-commerce have been chipping away at brick-and-mortar businesses over the years but the combination of the coronavirus pandemic and the 2020 holiday season may prove to be a knockout blow.

State of play: Anxious consumers say financial concerns and health worries will push them to spend less money this year and to do more of their limited spending online.

California to independently review FDA-approved coronavirus vaccines

California Gov. Gavin Newsom. Photo: Justin Sullivan/Getty Images

California will "independently review" all coronavirus vaccines approved by the Food and Drug Administration before allowing their distribution, Gov. Gavin Newsom (D) announced at a news conference Monday.

Why it matters: The move that comes days after NAID director Anthony Fauci said he had "strong confidence" in FDA-approved vaccines could cast further public doubt that the federal government could release a vaccine based on political motives, rather than safety and efficacy.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!